Growth abnormalities in children and adolescents with juvenile idiopathic arthritis

Rheumatology International

Volumn 34, Issue 11, 2014, Pages 1483-1488

  Bechtold, Susanne ^a   Simon, Dominique ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Growth; Growth hormone; Inflammation; Juvenile idiopathic arthritis; Short stature

Indexed keywords

ANTIRHEUMATIC AGENT; HUMAN GROWTH HORMONE;

ADOLESCENT; AGE; ARTHRITIS, JUVENILE; BODY COMPOSITION; BODY HEIGHT; CHILD; COMPLICATION; GROWTH DISORDERS; HUMAN; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BODY COMPOSITION; BODY HEIGHT; CHILD; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84937209143     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3022-2     Document Type: Review

References (48)

1. von Koskull S, Truckenbrodt H, Holle R, Hormann A (2001) Incidence and prevalence of juvenile arthritis in an urban population of southern Germany: a prospective study. Ann Rheum Dis 60:940–945
2. Simon D, Fernando C, Czernichow P, Prieur AM (2002) Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 29:1296–1300
3. Kotaniemi A (1997) Growth retardation and bone loss as determinants of axial osteopenia in juvenile chronic arthritis. Scand J Rheumatol 26:14–18
4. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V (2006) Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65:1044–1049
5. Liem JJ, Rosenberg AM (2003) Growth patterns in juvenile rheumatoid arthritis. Clin Exp Rheumatol 21:663–668
6. Still GF (1897) On a form of chronic joint disease in children. Med Chir Trans 80(47–60):49
7. Ansell BM, Bywaters EG (1956) Growth in still’s disease. Ann Rheum Dis 15:295–319
8. Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H, Schwarz HP (2007) Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 92:3013–3018
9. Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, Todisco N, Papale MR (1997) Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 26:99–103
10. Bechtold S, Beyerlein A, Ripperger P, Roeb J, Dalla Pozza R, Hafner R, Haas JP, Schmidt H (2012) Total pubertal growth in patients with juvenile idiopathic arthritis treated with growth hormone: analysis of a single center. Growth Horm IGF Res 22:180–185
11. Zak M, Muller J, Karup Pedersen F (1999) Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm Res 52:80–85
12. Rall LC, Roubenoff R (2004) Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 43:1219–1223
13. Bechtold S, Ripperger P, Bonfig W, Schmidt H, Bitterling H, Hafner R, Schwarz HP (2004) Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 31:1407–1412
14. Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M (2007) Osteoporosis in juvenile idiopathic arthritis: a practical approach to diagnosis and therapy. Eur J Pediatr 166:775–784
15. Knops N, Wulffraat N, Lodder S, Houwen R, de Meer K (1999) Resting energy expenditure and nutritional status in children with juvenile rheumatoid arthritis. J Rheumatol 26:2039–2043
16. Lofthouse CM, Azad F, Baildam EM, Akobeng AK (2002) Measuring the nutritional status of children with juvenile idiopathic arthritis using the bioelectrical impedance method. Rheumatology 41:1172–1177
17. Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA (1999) A 6-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res 14:1672–1679
18. Frost HM, Schonau E (2000) The “muscle-bone unit” in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 13:571–590
19. Burnham JM, Shults J, Sembhi H, Zemel BS, Leonard MB (2006) The dysfunctional muscle-bone unit in juvenile idiopathic arthritis. J Musculoskelet Neuronal Interact 6:351–352
20. Burnham JM, Shults J, Dubner SE, Sembhi H, Zemel BS, Leonard MB (2008) Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits. Arthritis Rheum 58:2518–2527
21. De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142:4818–4826
22. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Investig 99:643–650
23. Bergad PL, Schwarzenberg SJ, Humbert JT, Morrison M, Amarasinghe S, Towle HC, Berry SA (2000) Inhibition of growth hormone action in models of inflammation. Am J Physiol Cell Physiol 279:C1906–C1917
24. Thissen JP, Verniers J (1997) Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 138:1078–1084
25. von Laue S, Ross RJ (2000) Inflammatory cytokines and acquired growth hormone resistance. Growth Horm IGF Res 10(Suppl B):S9–S14
26. Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH, Cooney RN (2002) Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am J Physiol Endocrinol Metab 283:E472–E481
27. Jux C, Leiber K, Hugel U, Blum W, Ohlsson C, Klaus G, Mehls O (1998) Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 139:3296–3305
28. Fernandez-Vojvodich P, Palmblad K, Karimian E, Andersson U, Savendahl L (2012) Pro-inflammatory cytokines produced by growth plate chondrocytes may act locally to modulate longitudinal bone growth. Horm Res Paediatr 77:180–187
29. MacRae VE, Farquharson C, Ahmed SF (2006) The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol 189:319–328
30. De Benedetti F (2009) The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. Horm Res 72(Suppl 1):26–29
31. Fernandez-Vojvodich P, Karimian E, Savendahl L (2011) The biologics anakinra and etanercept prevent cytokine-induced growth retardation in cultured fetal rat metatarsal bones. Horm Res Paediatr 76:278–285
32. Fernandez-Vojvodich P, Zaman F, Savendahl L (2013) Interleukin-6 acts locally on the growth plate to impair bone growth. Ann Rheum Dis 72:24
33. Martensson K, Chrysis D, Savendahl L (2004) Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 19:1805–1812
34. Wong SC, MacRae VE, Gracie JA, McInnes IB, Galea P, Gardner-Medwin J, Ahmed SF (2008) Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like-growth factor axis. Growth Horm IGF Res 18:369–378
35. Schmeling H, Seliger E, Horneff G (2003) Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol 21:779–784
36. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW (2010) Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 62:3259–3264
37. Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, Wouters CH (2010) Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology 49:1550–1558
38. De Benedetti F (2013) Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med 368:1256–1257
39. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ. (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396–2406
40. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70:747–754
41. Svantesson H (1991) Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis: a pilot study. Clin Exp Rheumatol 9(Suppl 6):47–50
42. Davies UM, Jones J, Reeve J, Camacho-Hubner C, Charlett A, Ansell BM, Preece MA, Woo PM (1997) Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 40:332–340
43. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P (1998) Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab 83:403–409
44. Bechtold S, Ripperger P, Muhlbayer D, Truckenbrodt H, Hafner R, Butenandt O, Schwarz HP (2001) GH therapy in juvenile chronic arthritis: results of a 2-year controlled study on growth and bone. J Clin Endocrinol Metab 86:5737–5744
45. Bechtold S, Ripperger P, Hafner R, Said E, Schwarz HP (2003) Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 143:512–519
46. Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P (2007) Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 92:2567–2573
47. Hogler W, Shaw N (2010) Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol 72:281–289
48. Bechtold S, Ripperger P, Dalla Pozza R, Roth J, Hafner R, Michels H, Schwarz HP (2010) Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone. J Clin Endocrinol Metab 95:178–185